• KLRA share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Price change

    The price of KLRA shares has held flat since the market last closed. This is a 0.00% change.

  • Closed at $22.94.

    The stock has remained unchanged in after-hours trading.

Key terms

About KLRA

Kailera Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Its product candidate includes Ribupatide. The company was founded on May 08, 2024 and is headquartered in Waltham, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $2.97B

    A market capitalization between $2 billion and $10 billion places KLRA in the mid-capitalization category.

Key terms

Smart score

Latest KLRA news

May 28, 2026 11:55am ET Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA) by TipRanks May 27, 2026 5:35am ET Analyst Initiates Buy on Kailera, Citing Diversified GLP‑1 Pipeline and Pivotal 2027 Obesity Data Catalysts by TipRanks May 27, 2026 1:15am ET TD Cowen Reaffirms Their Buy Rating on Kailera Therapeutics, Inc. (KLRA) by TipRanks May 21, 2026 12:55pm ET Kailera Therapeutics, Inc. (KLRA) Receives a Buy from TD Cowen by TipRanks May 17, 2026 12:41pm ET Analysts Offer Insights on NA Companies: Arxis, Inc. Class A (ARXS) and Kailera Therapeutics, Inc. (KLRA) by TipRanks May 12, 2026 11:50am ET Kailera Therapeutics initiated with an Outperform at Evercore ISI by TipRanks May 12, 2026 7:41am ET Kailera Therapeutics initiated with an Outperform at Leerink by TipRanks May 12, 2026 5:37am ET Kailera Therapeutics initiated with a Buy at TD Cowen by TipRanks May 12, 2026 5:21am ET Analysts Offer Insights on NA Companies: Douglas AG (OtherDOUDF) and Kailera Therapeutics, Inc. (KLRA) by TipRanks May 12, 2026 5:15am ET Kailera Therapeutics initiated with an Outperform at William Blair by TipRanks May 12, 2026 5:10am ET Kailera Therapeutics initiated with an Overweight at JPMorgan by TipRanks May 12, 2026 5:06am ET Kailera Therapeutics initiated with a Buy at Jefferies by TipRanks May 11, 2026 2:44pm ET Opening Day: HawkEye 360 jumps in debut after high‑end pricing by TipRanks Apr 22, 2026 10:01pm ET Major Investor Makes Bold Move Into Kailera Therapeutics by TipRanks Apr 20, 2026 10:03pm ET Massive Insider Buying Spree Signals Surging Confidence in Kailera Therapeutics by TipRanks Apr 20, 2026 11:39am ET Opening Day: Drone maker AEVEX pops on debut by TipRanks Apr 17, 2026 2:40pm ET Kailera Stock (KLRA) Rockets 68% after IPO in Race for $150B Obesity Market by TipRanks Apr 17, 2026 1:30pm ET Kailera Therapeutics opens at $26, IPO priced at $16 per share by TipRanks Apr 17, 2026 11:45am ET Kailera Therapeutics indicated to open at $21, IPO priced at $16 by TipRanks Apr 17, 2026 10:40am ET Kailera Therapeutics indicated to open at $24, IPO priced at $16 by TipRanks Apr 16, 2026 8:05pm ET Kailera Therapeutics 39.06M share IPO priced at $16.00 by TipRanks
May 28, 2026 4:05pm ET Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference by GlobeNewswire May 26, 2026 4:02pm ET Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates by GlobeNewswire May 13, 2026 7:30am ET Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions by GlobeNewswire Apr 20, 2026 4:05pm ET Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares by GlobeNewswire Apr 16, 2026 7:25pm ET Kailera Therapeutics Announces Pricing of Initial Public Offering by GlobeNewswire

KLRA Financials

1-year income & revenue

  • KLRA total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • KLRA net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • KLRA earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

KLRA Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

KLRA Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range
  • How competitors are chosen

    KLRA's competitors are included in the Health Technology sector and Biotechnology group

  • Market cap: $2.97B

    A market capitalization between $2 billion and $10 billion places KLRA in the mid-capitalization category.

Key terms

Latest investing news